ClinicalTrials.gg
Not yet recruitingNCT07870278Updated Nov 16, 2026

A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)

A Phase 1 interventional study of MK-6255 and CD8 PET Tracer in Ovarian Neoplasms and Endometrial Neoplasms, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026First site in United StatesStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies in Ovarian Neoplasms by Merck & Co., Inc — 6 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · Merck & Co., Inc.

Planned enrollment
14th of 25
80 · median 132
Started
2026
with 3 others
Phase 1
8 of 27
1 open now
Registered
27th of 27
by date

Among the 27 studies in Ovarian Neoplasms by Merck & Co., Inc, this one is the 14th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 1, and was the 27th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 27 studies in Ovarian Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Ovarian Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment.

MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people.

The goals of this trial are to learn about:

  • The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems.
  • What happens to different dose levels (amounts) of MK-6255 in the body over time.
03

Conditions studied

  • Ovarian Neoplasms
  • Endometrial Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has one of the following diagnoses:

    • Recurrent, documented epithelial OC, primary peritoneal cancer, or fallopian tube cancer that is either (1) platinum resistant or (2) platinum sensitive, with progression during prior treatment with poly-adenosine diphosphate (ADP) ribose polymerase inhibitor (PARPi)
    • Histologically confirmed well, moderately, or poorly differentiated (ie, Grade 1 to Grade 3) serous or endometrioid EC that has progressed after at least 1 line of platinum-based therapy in any setting
  • Has received all protocol-required and available standard of care (SOC) therapies, unless ineligible for or intolerant to the therapies
  • Has provided or a recently obtained biopsy before treatment start
  • If living with (HIV), has well-controlled HIV on antiretroviral therapy (ART)
  • If surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral - therapy for at least 4 weeks
  • If history of virus (HCV) infection, has undetectable HCV viral load
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of any 1 of the following: Primary platinum- OC; neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas; carcinosarcoma; EC that is amenable to curative-intent surgery or curative-intent radiotherapy; or EC that requires recurrent drainage of effusions
  • Has a history of serious cardiovascular and cerebrovascular diseases
  • Has a history or presence of central nervous system (CNS) diseases
  • Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before start of study intervention
  • Has received prior radiotherapy within 2 weeks of start of study intervention
  • Has known additional that is progressing or has required active treatment within the past 3 years
  • Has known active and/or carcinomatous meningitis
  • Has active disease that has required systemic treatment in the past 2 years
  • Is living with and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has a history of stem cell/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants receive MK-6255 once every week (QW).

    Biological: MK-6255 · Other: CD8 PET Tracer · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Dexamethasone · Biological: Tocilizumab · Biological: Tocilizumab biosimilar · Biological: Siltuximab

  • Experimental
    Dose Interval Extension

    Participants receive MK-6255 at extended interval dosing.

    Biological: MK-6255 · Other: CD8 PET Tracer · Drug: Acetaminophen · Drug: Diphenhydramine · Drug: Dexamethasone · Biological: Tocilizumab · Biological: Tocilizumab biosimilar · Biological: Siltuximab

Interventions

  • BiologicalMK-6255

    During initial dose escalation, participants will receive MK-6255 one weekly (QW). During Dose Interval Extension, participants will receive target doses every 3 weeks (Q3W).

  • OtherCD8 PET Tracer

    Participants may receive an optional CD8 PET tracer for exploratory imaging assessments.

    Also known as: GEH200520, GEH200521 (18F)

  • Participants will receive acetaminophen (or similar antipyretic) as premedication.

  • Participants will receive diphenhydramine (or similar antihistamine) as premedication.

  • Participants will receive dexamethasone as premedication.

  • BiologicalTocilizumab

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

  • BiologicalTocilizumab biosimilar

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

    Also known as: Avtozma®, Tyenne®

  • BiologicalSiltuximab

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0

    A DLT is defined as any drug-related AE observed during the DLT evaluation period that meet criteria specified in the protocol. DLTs will be evaluated until 21 days after the first fixed dose during fixed-dose escalation and until 21 days after the first target dose during step-up dose escalation and dose interval extension.

    Time frame: Up to 21 days at each dose level

  2. Number of participants who experience one or more adverse events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that experience AEs will be reported.

    Time frame: Up to approximately 56 months

  3. Number of participants who discontinue study intervention due to an adverse event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants that discontinue study intervention due to an AE will be reported.

    Time frame: Up to approximately 56 months

Secondary outcomes

  1. Area Under the Serum Concentration-Time Curve (AUC) of MK-6255

    AUC is defined as the measure of overall drug exposure over time after administration. Blood samples will be collected to determine the AUC of MK-6255.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  2. Minimum Serum Concentration (Cmin) of MK-6255

    Cmin is defined as the lowest observed concentration of a drug after administration. Blood samples will be collected to determine the Cmin of MK-6255.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  3. Maximum Serum Concentration (Cmax) of MK-6255

    Cmax is defined as the highest observed concentration of a drug after administration. Blood samples will be collected to determine the Cmax of MK-6255.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  4. Time to Maximum Serum Concentration (Tmax) of MK-6255

    Tmax is defined as the time at which the maximum observed concentration of a drug occurs after administration. Blood samples will be collected to determine the Tmax of MK-6255.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2031, 55 months later.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 55 months is above that.

Counting every sponsor, half of 380 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
Jul 5, 2031
CompletionEst.
Jul 7, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in United States
Show site
  • START New Jersey ( Site 0808) · East Brunswick, United States
Nov 16, 2026
Contact
Study contact now listed: added T•••@merck.com · •••8839. See the current contact
Nov 16, 2026
Registered
First appeared on the registry
Oct 13, 2026
Show all 2 updates
  1. Nov 16, 2026
    1 site added — first site in United States
    Show site
    • START New Jersey ( Site 0808) · East Brunswick, United States
    Contact Study contact now listed: added T•••@merck.com · •••8839. See the current contact
    + 2 other changes: verification date and references
  2. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07870278
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Jul 5, 2031 (estimated)
Completion
Jul 7, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@merck.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion